Articles tagged with Pi3k Pathway
Researchers identified how prostate cancer cells achieve cell growth free from usual growth cues and regulators. A protein called PLEKHS1 was found to be a major driver of PI3K activation and cancer growth progression in mouse models.
A new chemical compound named '1938' has been identified that can stimulate nerve regeneration after injury and protect cardiac tissue from damage. The compound activates the PI3K signalling pathway and has shown increased neuron growth in nerve cells and improved recovery in animal models.
Researchers found that CUDC-907 selectively induces apoptosis in cells driven to senesce by p53 expression. The compound showed senolytic properties in different models of stress-induced senescence, depending on its inhibitory effects on HDACs and PI3K.
A protein called PI3K plays a crucial role in immune cell function, and genetic variations disrupting its signalling have been identified as the root cause of two immunodeficiency disorders. The study reveals how minor disruptions in immune cell signalling can lead to immune deficiency or dysfunction.
Researchers discovered a new personalized immunotherapy combination that treats aggressive forms of advanced prostate cancer. By blocking PD-1-expressing macrophages and Wnt/β-catenin pathway activation, the therapy significantly improves response rates in PTEN-deficient cancers.
ARID1A-deficient bladder cancers are sensitive to combination therapies with the EZH2 inhibitor GSK-126 and inhibitors of PI3K, acting synergistically. The research found that tumors deficient in ARID1A protein have elevated levels of PIK3R3 and phosphoAKT.
Research reveals tamoxifen boosts PI3K signaling, potentially increasing uterine cancer risk in breast cancer patients. Preclinical studies show PI3K inhibitor alpelisib mitigates this effect.
The study found that combining mTORC1 and PLK1 inhibitors showed high antitumor activity in NSCLC, with synergistic effects observed. The combination may target specific biomarkers of resistance to Pi3K-based monotherapies, offering a promising therapeutic approach.
Research found that combining copanlisib with cetuximab significantly improves treatment outcomes in head and neck squamous cell carcinoma (HNSCC) patients. The study suggests PI3K inhibition as a potential biomarker for predicting treatment responses.
Researchers have identified a potential therapeutic strategy for obesity by discovering the signalling pathways responsible for the development of adipose tissue macrophages (ATMs) in obesity. ATMs play a key role in preventing lipotoxicity, where fat molecules are deposited in non-adipose tissues.
Research suggests that PI3K inhibitors, a new class of cancer drugs, may cause an increase in pre-cancerous lesions in the pancreas of mice fed high-fat diets. The findings urge doctors to consider a patient's weight before prescribing these drugs, especially for those with pancreatic cancer who are obese.
Dr. Lewis C. Cantley is being recognized for his groundbreaking work in discovering the phosphoinositide 3-kinase (PI3K) enzyme and elucidating its role in cancer development. His research has led to the development of personalized cancer therapies targeting the PI3K signaling pathway.
Researchers at MDC Berlin-Buch have identified a critical enzyme, PI3K, that enables c-MYC to transform B lymphocytes into malignant cells. This finding may lead to effective treatments by inhibiting the PI3K signaling pathway.
The study reveals cell-type specificity of PI3K signaling in the mammalian brain, with PTEN tumor suppressor protein playing a crucial role. PDK1 deletion shows selective increase in AKT phosphorylation in glial cells, suggesting personalized cancer treatment approaches.
Researchers have identified a potential mechanism for treating multiple sclerosis using IFN-beta, which reduces disease in a mouse model by inducing IL-27 secretion. Meanwhile, a new study on sickle cell disease suggests that bosentan prevents organ damage by inhibiting endothelin receptor activation. Leptin signaling also plays a cruc...
Cantley's discovery of the PI3K signaling pathway has helped explain how normal cells turn into cancerous cells, providing a key target for future cancer treatments. His work has progressed from identifying an unusual lipid kinase activity to uncovering its central role in controlling cancer cell growth and survival.